Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma
- 26 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 40 (9), 1659-1673
- https://doi.org/10.1038/s41388-020-01628-x
Abstract
The clinical benefit of MAPK pathway inhibition in melanoma patients carrying BRAF mutations is temporal. After the initial response to treatment, the majority of tumors will develop resistance and patients will relapse. Here we demonstrate that the endothelin-endothelin receptor B (ETBR) signaling pathway confers resistance to MAPK pathway inhibitors in BRAF mutated melanoma. MAPK blockade, in addition to being anti-proliferative, induces a phenotypic change which is characterized by increased expression of melanocyte-specific genes including ETBR. In the presence of MAPK inhibitors, activation of ETBR by endothelin enables the sustained proliferation of melanoma cells. In mouse models of melanoma, including patient-derived xenograft models, concurrent inhibition of the MAPK pathway and ETBR signaling resulted in a more effective anti-tumor response compared to MAPK pathway inhibition alone. The combination treatment significantly reduced tumor growth and prolonged survival compared to therapies with MAPK pathway inhibitors alone. The phosphoproteomic analysis revealed that ETBR signaling did not induce resistance towards MAPK pathway inhibitors by restoring MAPK activity, but instead via multiple alternative signaling pathways downstream of the small G proteins GNAq/11. Together these data indicate that a combination of MAPK pathway inhibitors with ETBR antagonists could have a synergistically beneficial effect in melanoma patients with hyperactivated MAPK signaling pathways.This publication has 44 references indexed in Scilit:
- Endothelin 1 in cancer: biological implications and therapeutic opportunitiesNature Reviews Cancer, 2013
- An Antibody–Drug Conjugate Targeting the Endothelin B Receptor for the Treatment of MelanomaClinical Cancer Research, 2011
- Endothelin: 20 years from discovery to therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.Canadian Journal of Physiology and Pharmacology, 2008
- Endothelin Receptor B Inhibition Triggers Apoptosis and Enhances Angiogenesis in MelanomasCancer Research, 2004
- Endothelin-B Receptor Blockade Inhibits Molecular Effectors of Melanoma Cell ProgressionJournal of Cardiovascular Pharmacology, 2004
- Endothelin B Receptor Blockade Inhibits Dynamics of Cell Interactions and Communications in Melanoma Cell ProgressionCancer Research, 2004
- Expression of the endothelin-B receptor in pigment cell lesions of the skinVirchows Archiv, 2001
- Molecular classification of cutaneous malignant melanoma by gene expression profilingNature, 2000
- An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivoProceedings of the National Academy of Sciences of the United States of America, 1999
- Human Melanoma Cells Express Functional Endothelin-1 ReceptorsBiochemical and Biophysical Research Communications, 1994